| Title： | Expert Consensus on Off-label Use in the Treatment of COVID-19 Infection |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinical physicians at all levels (including pharmacy and other relevant fields) |
| Evidence classification method： | Thomson grading system |
| Development unit： | Sun Yat-sen Memorial Hospital, Sun Yat-sen University |
| Registration time: | 2023-01-08 |
| Registration number： | PREPARE-2023CN017 |
| Purpose of the guideline: | In recent years, the treatment of patients with COVID-19 infection has been a major focus in the medical field. Although a number of drugs have been marketed for the treatment of COVID-19 infection in China, with the continuous updating of COVID-19 treatment regimens and the accessibility of drugs, the approved indications, applicable population, dosage, and route of administration of drug label are not sufficient to meet the real-world treatment needs. The off-label use of drugs indeed exists objectively, and its scientificity and rationality is in urgent need of discussion. This consensus aims to conduct evidence-based evaluation of off-label use in the treatment of COVID-19 infection based on the contents of domestic and foreign drug label registration, guideline, consensus, clinical research and other evidence-based medical evidence, and then the expert recommendation of off-label use in the treatment of COVID-19 infection will be formed by the expert group, so as to provide the basis for rational drug use for clinicians and further standardize the clinical application of off-label use of drugs for COVID-19 infection. |
Latest registration
